SEC Form 4 · accession 0001615774-18-001262
Tonix Pharmaceuticals Holding Corp. · TNXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bradley Saenger
Officer — Chief Financial Officer
Period of report
Feb 13, 2018
Accepted (ET)
Feb 15, 2018 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001430306
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F1 | $3.40 | Feb 13, 2018 | A | 39,150 | A | Feb 13, 2019 | Feb 12, 2028 | Common Stock | 39,150 | 39,150 | D |
| Stock OptionF2,F1 | $4.25 | Feb 13, 2018 | A | 39,150 | A | Feb 13, 2019 | Feb 12, 2028 | Common Stock | 39,150 | 39,150 | D |
Explanation of responses
- F1The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
- F2The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan.